NTRK1 and osteosarcoma: Larotrectinib, an ATP-competitive inhibitor with nanomolar affinity for all Trk isoforms, curtailed orthotopic osteosarcoma expansion and abolished experimental lung metastases in a murine model driven by NGF over-expression, an effect accompanied by reduced MEK/ERK activity and restoration of miR-92a-1-5p levels (71, 72).